Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) — Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), […]